Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. JSPR
JSPR logo

JSPR

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

JSPR News

Jasper Appoints Jeet Mahal as CEO, Focuses on Chronic Urticaria Treatment

Jan 07 2026Globenewswire

Jasper Stock Soars Following Positive Results from New Asthma Study

Dec 02 2025Benzinga

Jasper Reports Positive ETESIAN Study Data for Briquilimab, 180mg Dose Shows Significant Asthma Improvement

Dec 02 2025Globenewswire

Jasper Reports Positive ETESIAN Study Data for Briquilimab, 180mg Dose Shows Significant Asthma Improvement

Dec 02 2025Newsfilter

Jasper Therapeutics Announces Encouraging Findings for Briquilimab in Phase 1b Study of Allergic Asthma

Dec 02 2025NASDAQ.COM

Jasper Therapeutics to Hold Webinar Showcasing Results from BEACON and ETESIAN Studies

Dec 02 2025NASDAQ.COM

Post-Market Highlights: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, and Protara See Gains After Trading Hours

Dec 02 2025NASDAQ.COM

Jasper Therapeutics to Host Webinar Presenting briquilimab Study Findings

Dec 01 2025Newsfilter

Bragar Eagel & Squire Investigates Officers and Directors of Driven Brands and Jasper Therapeutics for Long-Term Stockholders, Urging Investors to Reach Out to the Firm

Nov 22 2025Globenewswire

IMPORTANT NOTICE for NX, JSPR, and KBR: The Law Offices of Frank R. Cruz Notifies Investors About Class Action Lawsuits for Shareholders

Nov 18 2025Globenewswire

JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces Opportunity for Jasper Therapeutics, Inc. Investors Facing Significant Losses to Initiate Class Action Lawsuit

Nov 18 2025Globenewswire

Bragar Eagel & Squire, P.C. Alerts Jasper, KBR, Spirit, and Molina Stockholders About Approaching Deadlines and Encourages Investors to Reach Out to the Firm

Nov 17 2025Globenewswire

JSPR DEADLINE: ROSEN, A TOP INVESTOR LAW FIRM, Urges Jasper Therapeutics, Inc. Shareholders to Obtain Legal Representation Ahead of Key November 18 Deadline in Securities Class Action – JSPR

Nov 16 2025Globenewswire

JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR

Nov 14 2025PRnewswire

IMPORTANT NOTICE for NX, JSPR, KBR, RICK: Law Offices of Howard G. Smith Notify Shareholders About Chance to Head Securities Fraud Class Actions

Nov 14 2025Globenewswire

Jasper Therapeutics, Inc. Faces Lawsuit for Securities Law Breaches - Reach Out to DJS Law Group to Understand Your Rights – JSPR

Nov 14 2025Globenewswire